The FDA Issued Determination Letter For Mimedx's Request For Designation Noting Axiofill Does Not Meet Regulatory Classification Requirements Of A Human Cell, Tissue, Or Cellular Or Tissue-based Product
Author: Benzinga Newsdesk | March 27, 2024 08:09am